ESCs require PRC2 to direct the successful reprogramming of differentiated cells toward pluripotency.

Pereira CF; Piccolo FM; Tsubouchi T; Sauer S; Ryan NK; Bruno L; Landeira D; Santos J; Banito A; Gil J; Koseki H; Merkenschlager M; Fisher AG

doi:10.1016/j.stem.2010.04.013

ESCs require PRC2 to direct the successful reprogramming of differentiated cells toward pluripotency.

ARTICLE PUBLISHED: 2010 Jun 04

CITE AS: Cell Stem Cell. 2010 Jun 04; 6(6):547-556 https://doi.org/10.1016/j.stem.2010.04.013

You have reached your article limit.

Register for 30-day free trial

Registration is free and only takes a moment, or subscribe for unlimited access.
Register
Already registered with F1000Prime?

Sign In

Institutional access

Recommend F1000Prime to your librarian or information manager to request an extended free trial for all users at your institution.
Recommend to your librarian

F1000Prime is an expert-curated resource to help you find the articles of greatest interest and relevance to you.
Embryonic stem cells (ESCs) are pluripotent, self-renewing, and have the ability to reprogram differentiated cell types to pluripotency upon cellular fusion. Polycomb-group (PcG) proteins are important for restraining the inappropriate expression of lineage-specifying factors in ESCs. To investigate whether PcG proteins are required for establishing, rather than maintaining, the pluripotent state, we compared the ability of wild-type, PRC1-, and PRC2-depleted ESCs to reprogram human lymphocytes. We show that ESCs lacking either PRC1 or PRC2 are unable to successfully reprogram B cells toward pluripotency. This defect is a direct consequence of the lack of PcG activity because it could be efficiently rescued by reconstituting PRC2 activity in PRC2-deficient ESCs. Surprisingly, the failure of PRC2-deficient ESCs to reprogram somatic cells is functionally dominant, demonstrating a critical requirement for PcG proteins in the chromatin-remodeling events required for the direct conversion of differentiated cells toward pluripotency.

Copyright 2010 Elsevier Inc. All rights reserved.

PMID: 20569692
Funding information

This work was supported by:
- Medical Research Council, United Kingdom
  
  Grant ID: MC_U120085810
- Medical Research Council, United Kingdom
  
  Grant ID: MC_U120027516
0 Comments

Relevant Sections

Genomics & Genetics
- Animal Genetics
- Epigenetics & Epigenomics
Developmental Biology
- Developmental Molecular Mechanisms
- Stem Cells & Regeneration

Add comment

User comments must be in English, comprehensible and relevant to the article under discussion. F1000 reserves the right to remove any comments that it considers in its absolute discretion to be inappropriate, offensive or otherwise in breach of the Terms and Conditions relating to Materials (including Comments).

This entry form currently does not support special characters.

15,000 characters

Please type your message

Disclosures. Please disclose any competing interests that might be construed to influence your judgment of the validity or importance of the article, or any recommendation or review.

Disclosures Policy

Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list:

Examples of 'Non-Financial Competing Interests'

Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.
You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.
You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).
You work at the same institute as any of the authors.
You hope/expect to benefit (e.g. favour or employment) as a result of your submission.
You are an Editor for the journal in which the article is published.

Examples of 'Financial Competing Interests'

You expect to receive, or in the past 4 years have received, any of the following from any commercial organization that may gain financially from your submission: a salary, fees, funding, reimbursements.
You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.
You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.

4,000 characters

I am an author of this article

I am a Faculty Member who recommended this article

Neither of the above

You must select a comment type

Terms & conditions

The use of certain tools provided by this website is subject to additional Terms and Conditions. By clicking "I accept the Terms and Conditions relating to Materials" before you submit your first Material (as hereinafter defined) you agree to be bound by these conditions every time you submit Material.

This Agreement shall begin on the date hereof.
Certain parts of this website offer the opportunity for users to post opinions, information and material including without limitation academic papers and data ('Material') in areas of the website. F1000 does not claim any ownership in the Material that you or any other user posts. F1000 does not screen, edit, publish or review Material prior to its appearance on the website and is not responsible for it. Material does not reflect the views or opinions of F1000, its agents or affiliates. Any view or opinion expressed in any Material is the view or opinion of the person who posts such view or opinion. To the extent permitted by applicable laws F1000 shall not be responsible or liable for the Material or for any loss cost, liability, damages or expenses caused and or suffered as a result of any use of and/or reliance on and/or posting of and/or appearance of the Material on this website
You may only use this website for lawful purposes. Accordingly you may only post Material that you have the right to do so.
You may not use the website for any unlawful purpose, including without limitation, to upload, post, download or otherwise use any Material that you do not have the copyright owners permission to so upload, post, download or otherwise use, or that would result in you being in breach of these terms and conditions.
F1000 reserves the right to monitor all Material and to remove any Material which it considers in its absolute discretion to be unlawful, inappropriate, offensive or otherwise in breach of these Terms and Conditions.
By posting or uploading Material you warrant and represent that:
1. You are entitled to post or upload the Material on the website and have all necessary licenses and consents to do so;
2. the Material does not infringe any intellectual property right, including without limitation copyright, patent or trademark, or other proprietary right of any third party;
3. the Material does not contain any defamatory, libellous, offensive, indecent or otherwise unlawful material or material which is an invasion of privacy;
4. the Material does not contain any contaminating or destructive features or devices such as viruses, time bombs or coding designed to interrupt, destroy or limit the functionality of this website or any of this website's user's computer equipment or software;
5. the Material will not be used to solicit or promote business or custom or present commercial activities or unlawful activity; and
6. the Material is in compliance with all applicable laws.
By posting Material you grant to F1000 an irrevocable non-exclusive royalty-free license to keep a copy of Material for a reasonable period and as necessary to enable it to comply with its legal obligations.
You hereby agree to indemnify and keep indemnified F1000, its affiliates, contractors and agents from and against any and all losses (including without limitation direct, indirect and consequential loss), costs, claims, damages or expenses of whatever nature and howsoever caused arising directly or indirectly from any breach of these Terms and Conditions or arising from the Material posted on this website or content contained in any email sent using the facilities provided by the website by you including without limitation as a result of any infringement of any intellectual property or other proprietary rights, libel, defamation, obscenity or the Material being otherwise unlawful.
These terms shall be governed by and construed in accordance with English Law.

* I accept the Terms and Conditions relating to Materials (including Comments)

I would like to receive updates when further comments, recommendations, or dissenting opinions are publishing on this article.

ESCs require PRC2 to direct the successful reprogramming of differentiated cells toward pluripotency.

You have reached your article limit.

Register for 30-day free trial

Institutional access

F1000Prime is an expert-curated resource to help you find the articles of greatest interest and relevance to you.

Funding information

Medical Research Council, United Kingdom

Medical Research Council, United Kingdom

Make sure you nevermiss a key paper

ESCs require PRC2 to direct the successful reprogramming of differentiated cells toward pluripotency.

Add comment

Email article details

Sign in

Authenticate via your institution

Make sure you never
miss a key paper